Do the current LBP guidelines for primary care have it right? If so, are you up-to-date on them? Find out with our 11-question quiz.
Cebranopadol Achieves Positive Phase 3 Results for Treatment of Moderate-to-Severe Acute Pain
January 22nd 2025Cebranopadol, an investigational oral dual-NMR agonist, satisfied the primary endpoint of statistically significant reduction in pain intensity compared to placebo following abdominoplasty surgery.